A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
The pivotal portion of bardoxolone’s Cardinal study can’t match earlier data, but is still sufficient for filing.
Fresh from buying omaveloxolone and bardoxolone rights back from Abbvie, Reata sees the first part of the puzzle fall into place.